Literature DB >> 15602181

Disability among U.S. Army personnel vaccinated against anthrax.

Sandra I Sulsky1, John D Grabenstein, Rachel Gross Delbos.   

Abstract

This study was conducted to examine whether U.S. Army personnel receiving > or =1 dose of anthrax vaccine adsorbed (AVA) between March 1998 and February 2002 were at higher risk of disability than unvaccinated personnel. We studied a historical cohort study of 716,833 active-duty soldiers (154,456 vaccinated) followed for 4.25 years to determine rates of evaluation for disability discharge. Cox proportional hazards models compared estimated risk of evaluation for disability, accounting for occupation and sociodemographics. Adjusted hazard ratio (HR) and 95% confidence interval (CI) was 0.96 (CI = 0.92-0.99). Separate adjusted HRs for men, women, permanent and temporary disability, musculoskeletal and neurologic conditions were similar, ranging from 0.90 to 1.04. Latency assumptions did not affect results. Anthrax vaccination does not increase risk of disability. This finding may be partially the result of factors influencing selection for vaccination or vaccine tolerance.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15602181     DOI: 10.1097/01.jom.0000141664.90587.47

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Authors:  Tracy Pondo; Charles E Rose; Stacey W Martin; Wendy A Keitel; Harry L Keyserling; Janiine Babcock; Scott Parker; Robert M Jacobson; Gregory A Poland; Michael M McNeil
Journal:  Vaccine       Date:  2014-04-24       Impact factor: 3.641

Review 2.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.